Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | STK11 loss |
Therapy | Avelumab + Talazoparib |
Indication/Tumor Type | lung non-squamous non-small cell carcinoma |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
STK11 loss | lung non-squamous non-small cell carcinoma | no benefit | Avelumab + Talazoparib | Phase II | Actionable | In a Phase II trial (SWOG S1900C, LUNG-MAP sub-study), Talzenna (talazoparib) and Bavencio (avelumab) combination therapy did not meet the efficacy threshold in patients with advanced or recurrent non-squamous non-small cell lung cancer harboring STK11 pathogenic mutations or biallelic loss, resulting in an objective response rate of 2% (1/47) and a disease control rate at 12 weeks of 40% (17/47) (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 9060; NCT04173507). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507). | Full reference... |